High hopes as Inventiva takes NASH contender into phase 3
pharmaphorum
JANUARY 6, 2021
Analysts are continuing to back Inventiva’s lanifibranor as a potential “best-in-class” drug for the fatty liver disease NASH, as the company prepares for the launch of a phase 3 trial in spring. The trial will take a while however, with results not due until the second half of 2023, with sales forecast to peak at around $2.6
52 
Let's personalize your content